The recent development in the European Union’s court proceedings might very well have a significant impact on deal probes throughout the region. This comes as an aide to the European Union’s top court, Advocate General Nicholas Emiliou, criticized EU regulators for exceeding their authority while investigating the Illumina Inc.’s dropped $7 billion purchase of cancer-test provider Grail Inc.
According to Bloomberg Law, Emiliou’s stance, which is non-binding but influential, states that the European Commission’s choice to initiate a previously unused deal-assessment procedure, Article 22, extended the scope of merger regulations unlawfully in this particular case.
The fears are not underserved as the said procedure, if accepted, could potentially grant the Commission collective authority over reviewing nearly all concentrations with a significant impact on competition in the European Internal Market.
Such a dramatic expansion of power is, as Emiliou pointed out, unjustified, as it pushes the concept of a ‘de facto universal’ jurisdiction, potentially impinging upon the procedural rights of the parties involved.
This situation leaves the future of EU deal probes hanging in the balance. As the court’s final ruling remains pending, the repercussions could be a major setback for the European Commission.
Legal professionals and corporations should pay careful attention to this unfolding scenario, as its outcome has the potential to redefine the mechanisms of the Commission’s merger controls and by extension, the landscape of EU corporate law.